Contemporary Evidence-Based Management of Sinonasal Malignancies (2023 AMW)
2023 AAO-HNSF Annual Meeting & OTO Experience
We will present an overview of contemporary management of sinonasal cancers from diagnosis to survivorship. We will present a summary of updates in staging, work up and newly identified histological subtypes such as SMARC-B1 deficient carcinoma, NUT carcinoma. We will discuss broad principles and differences in treatment by tumor groups, including squamous cell carcinoma, minor salivary gland tumors, neuroendocrine cancers including olfactory neuroblastomas and sinonasal undifferentiated carcinomas. We will briefly discuss recent advances in multimodality therapy (including chemotherapy, targeted therapy, immunotherapy and radiotherapy), strategies for organ preservation and quality of life considerations. Lastly, we will discuss evidence-based decision-making to develop a comprehensive treatment plan for patients with sinonasal cancers including surveillance and follow up.Significance & Relevance: Sinonasal cancers are rare but aggressive malignancies that are poorly understood. Diagnosis, staging and treatment are rapidly evolving. There are few evidence-based, published guidelines and the paucity of clinical trials pose a challenge to identifying best practice. Moreover, sinonasal malignances and their treatment may impact critical organ systems resulting in functional impairments. Multi-disciplinary treatment is paramount to improving survival and quality of life. This presentation will focus on multimodality therapy and updates in diagnosis, treatment and best-practice in survivorship care. We believe this will be informative for both trainees and practicing surgeons.
Credits
CME:1.0, MOC:1.0